Personalized medicine: Elusive dream or imminent reality?

Clinical Pharmacology and Therapeutics

Volumn 81, Issue 6, 2007, Pages 807-816

  Lesko, L J ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CLOZAPINE; DIGOXIN; ERLOTINIB; GEFITINIB; ILOPERIDONE; IMATINIB; IRINOTECAN; MARAVIROC; ROFECOXIB; TORCETRAPIB; TRASTUZUMAB; WARFARIN;

AGRANULOCYTOSIS; BLEEDING; BREAST CANCER; CLINICAL PRACTICE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DRUG DELIVERY SYSTEM; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; GENETIC POLYMORPHISM; GENETICS; GENOMICS; GENOTYPE; HEALTH CARE; HEALTH CARE COST; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG NON SMALL CELL CANCER; MATHEMATICAL MODEL; MEDICAL TECHNOLOGY; MEDICINE; MYELOID LEUKEMIA; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; PRODUCTIVITY; REVIEW; RISK ASSESSMENT; SAFETY; SCHIZOPHRENIA; SCIENCE; SOCIAL STATUS; STROKE; VALIDATION PROCESS;

BIOMEDICAL RESEARCH; BIOMEDICAL TECHNOLOGY; DRUG INDUSTRY; DRUG THERAPY; GENOMICS; HUMANS; MODELS, BIOLOGICAL; MOLECULAR DIAGNOSTIC TECHNIQUES; PHARMACOGENETICS; PHARMACOLOGY, CLINICAL; PRODUCT SURVEILLANCE, POSTMARKETING; RANDOMIZED CONTROLLED TRIALS;

EID: 34249028688     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100204     Document Type: Review

References (20)

1. Humphries, K.H., Kerr, C.R. & Connolly, S.J. et al. New-onset atrial fibrillation. Circulation 103, 2365-2370 (2001).
2. Breckenridge, A., Orme, M. & Wesseling, H. et al. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin. Pharmacol. Ther. 15, 424-430 (1974).
3. Rieder, M.J., Reiner, A.P. & Gage, B.F. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. New Engl. J. Med. 352, 2285-2293 (2005).
4. Gladwell, M. Blink-the Power of Thinking Without Thinking, (Little Brown and Company, New York, NY, 2005).
5. Woodcock, J. The prospects for personalized medicine in drug development and in drug therapy. Clin. Pharmacol. Ther. 81, 164-169 (2007).
6. Marchione, M. Breast cancer decline tied to less use of hormones. South Florida Sun Sentinel, p. 18A, December 15, 2006.
7. Naisbitt, J. Mind Set - Reset Your Thinking and see the Future, (Harper Collins, New York, NY, 2006).
8. Accessed at http://www.affymetrix.com/index.affx.
9. Accessed at http://www.twt.com/company/pressreleases/2006/March_2_206. htm.
10. Food and Drug Administration Innovation or stagnation: challenges and opportunity on the critical path to new medical products (March 2004). Accessed at http://www.fda.g0v/oc/initiatives/criticalpath/whitepaper.html.
11. Pfizer maraviroc assay in HIV is model for personalized medicine, firm says. The Pink Sheet 68(051), p. 11, December 18, 2006.
12. Vanda: tiny PhRMA, big opportunity, BusinessWeek.com, December 7, 2006.
13. Pfizer stops all torcetrapib clinical trials in interest of patient safety. Accessed at http://www.fda.gov/bbs/topics/NEWS/2006/NEW01514.html.
14. PGxPredict: Clozapine Test. Accessed at http://www.pgxhealth.com/ genetictests/clozapine.
15. Accessed at http://www.genzyme.com/b2b/services_testing.asp.
16. MDVIP-Exceptional doctors, exceptional care, exceptional results. Accessed at http://www.mdvip.com.
17. Accessed at http://www.mdvip.com/NewCorpWebSie/VeryImportantPatients/ PartnersinPractice.
18. Accessed at http://biz.yahoo.com/prnews/061130/sfth062.html?.v=74.
19. Accessed at http://biz.yahoo.com/prnews/061205/cgtu037.html?. v83&printer=1.
20. Sheiner, L.B. Learning vs. confirming in clinical drug development. Clin. Pharmacol. Ther. 61, 275-279 (1997).